Documents/Mandatory-Directives
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
International Symposium on Novel Ideas in Science and Ethics Of
I N T E R N A T I O N A L S Y M P O S I U M O N N O V E L I D E A S I N S C I E N C E A N D E T H I C S O F V A C C I N E S A G A I N S T C O V I D - 1 9 P A N D E M I C 30 JULY 2020 DEPARTMENT OF HEALTH RESEARCH MINISTRY OF HEALTH AND FAMILY WELFARE, GOVERNMENT OF INDIA International Symposium on Novel ideas in Science and Ethics of Vaccines against COVID-19 pandemic Date: 30th July 2020 / 4:30 pm – 6:45 pm IST (A fully online, multi-country program) Moderated / Facilitated by Chris Anderson, Curator, TED talks Follow Live at - https://icmrvaccines.impcom.in/ Timing (IST) Session Speakers / Discussants Prof K VijayRaghavan Principal Scientific Advisor to Govt. of India Dr Renu Swarup Secretary, Dept of Biotechnology, Government of India 16.30 – 16:36 Welcome and Introductory Statement Prof Heidi Larson Director of The Vaccine Confidence Project (VCP); Professor, London School of Hygiene and Tropical Medicine, UK Prof Adam Kamradt-Scott Director, Global Health Security Network, Associate Professor, University of Sydney, Australia 16:36 – 16:41 Confronting the pandemic Dr Anthony S Fauci Director, National Institute of Allergy and Infectious Diseases, USA 16:42 – 16:43 A short Video Timely & Safe – Towards a Covid-19 Prof Peter Piot vaccine (Leadership remarks)- Role of Director, London School of Hygiene and Tropical Medicine, UK vaccines in ending epidemics Prof Stanley Plotkin 16:45 – 17:06 Introduced by: Mr JVR Prasada Rao Author of Plotkin’s Vaccines, Emeritus Professor, University of Pennsylvania, USA National Task Force COVID-19 member and Former Secretary for Health, Govt. -
The Blood in the Freezer Botswana Leads in HIV Treatment
HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH AIDS INITIATIVE spotlight spring 2016 Botswana Leads in HIV Treatment Billions of dollars are spent every year on HIV/AIDS treatment programs. But how well are they working? In the African country of Botswana, where 25% of adults (aged 16-49) are HIV positive, the answer is extremely well. In a recent paper in The Lancet HIV, researchers showed that Botswana is close to reaching the ambitious UNAIDS 90-90-90 goals. Photo by Dominic Chavez In 2014, UNAIDS proposed new testing and treatment targets directed towards ending the AIDS epidemic: by the year 2020, 90% The Blood in the Freezer of all HIV-infected people would know their HIV status; 90% of those diagnosed with HIV would One tiny vial of blood contains a re- at the BHP headquarters in Gaborone, be on antiretroviral therapy (ART); markable amount of genetic informa- Botswana. Most are blood samples and 90% of those on ART would tion about both the person from whom collected from tens of thousands of have a suppressed viral load (very it was drawn and infectious agents like patients who have participated in BHP low levels of HIV in their blood). A HIV circulating at the time of the needle clinical trials over the past 20 years. growing body of research shows prick. Because HIV mutates so quickly, Besides blood samples, the biorepository that providing ART to people living having access to lots of samples to study also includes specimens of hair, tissue, with HIV, besides being good for is a valuable resource. -
January-March 2009
ISSN 2040-1450 HIV treatment bulletin S O U T H Volume 2 Number 1 January-March 2009 C O N T E N T S EDITORIAL 2 TREATMENT ACCESS 13 CONFERENCE REPORTS 3 • FDA approval of generic ARVs 16th Conference on Retroviruses and Opportunistic Infections • Lost benefit of ARVs in South Africa 8-11 February 2009, Montreal DRUG INTERACTIONS 15 • Introduction • Recent reports on new drug interactions • High rates of HIV acquisition in pregnancy and post partum in • Drug interactions with integrase inhibitors Francistown, Botswana • Serum bilirubin increases when PEG-interferon and ribavirin • Risk factors for adverse pregnancy outcomes in Botswana are used with atazanavir CONFERENCE REPORTS 5 • Drug interactions between efavirenz and itraconazole 9th International Congress on Drug Therapy in HIV Infection, 9-13 • Effect on tacrolimus when switching from nelfinavir to November 2008, Glasgow fosamprenavir • Introduction • Elvitegravir with tipranavir/ritonavir or darunavir/ritonavir • Summary of antiretroviral studies at Glasgow BASIC SCIENCE 16 • The Antiretroviral Pregnancy Registry: individual drug • Cause for caution on HIV cure report safety reports on health of infants exposed to ARVs during • Low-level HIV replication versus latency: identifying the source pregnancy of viral rebounds during treatment interruption • Initial results from PENTA 11 trial of planned treatment OTHER NEWS 17 interruptions in children • EMEA supports extension of D:A:D study until at least 2012 • Inflammation and coagulation markers askew in children with and the new -
San Bernardino County Waiting, for Now, to Expand Stage 2 Coronavirus Reopening – Redlands Daily Facts
San Bernardino County waiting, for now, to expand Stage 2 coronavirus reopening – Redlands Daily Facts LOCAL NEWS • News San Bernardino County waiting, for now, to expand Stage 2 coronavirus reopening By SANDRA EMERSON | [email protected] | PUBLISHED: May 19, 2020 at 4:58 p.m. | UPDATED: May 19, 2020 at 10:37 p.m. While San Bernardino County supervisors are eager for restaurants and churches to resume operations after weeks of novel coronavirus-related closures and restrictions, they’re waiting to see how the county’s data pairs with new state guidelines on reopening various sectors. After a lively debate Tuesday, May 19, about the risks associated with reopening ahead of the state, the supervisors agreed to hear more from county staff before expanding the second of the state’s four-phase plan to reopen businesses. Supervisors agreed to meet at 4 p.m. Thursday, May 21, to further discuss the matter. “Our small businesses have sat and waited,” Supervisor Robert Lovingood said. “They’ve waited patiently as long as they can. They cannot suffer this economic suppression any longer.” Lovingood and Supervisor Dawn Rowe supported moving forward with the county’s recovery plan, which assesses the risk of the virus’ spread at businesses and offers guidelines for reopening safely. However, the item was not on the agenda, so the board agreed to schedule a special meeting. https://www.redlandsdailyfacts.com/2020/05/19/san-bernardino-county-waiting-for-now-to-expand-stage-2-coronavirus-reopening/[5/20/2020 8:18:00 AM] San Bernardino County waiting, for now, to expand Stage 2 coronavirus reopening – Redlands Daily Facts TOP ARTICLES 1/5 S A By .st0{fill:#FFFFFF;}.st1{fill:#0099FF;} M READ MORE Thousands evacuated as river dams break in central “This is a serious thing we have to do in the right way,” Chairman Curt Hagman said. -
The Annual MIDAS Network Meeting Takes Place April 3-5, 2018, at the Hyatt Regency Bethesda. Registration and Other Informatio
MIDAS CIDID Newsletter #14 View this email in your browser Issue #14 | February 2018 Welcome to the February 2018 edition of the MIDAS CIDID Newsletter. This is where you can nd Center-wide updates, along with relevant news and highlights. CIDID Website CIDID Twitter The annual MIDAS Network Meeting takes place April 3-5, 2018, at the Hyatt Regency Bethesda. Registration and other information is available on the MIDAS meeting website. The 10th Summer Institute in Statistics and Modeling in Infectious Diseases (SISMID) takes place July 9-25, 2018, at the University of Washington in Seattle. Registration and scholarship information is available on the SISMID website. Seroprevalence of Dengue Antibodies in Three Urban Settings in Yucatan, Mexico AJTMH [pdf] An Assessment of Household and Individual-Level Mosquito Prevention Methods during the Chikungunya Virus Outbreak in the United States Virgin Islands, 2014–2015 AJTMH [pdf] Core pertussis transmission groups in England and Wales: A tale of two eras Vaccine [pdf] Resilience management during large-scale epidemic outbreaks Scientic Reports [pdf] Panel data analysis via mechanistic models arXiv [pdf] Models and analyses to understand threats to polio eradication BMC Medicine [pdf] Comparative epidemiology of poliovirus transmission Scientic Reports [pdf] Silent circulation of poliovirus in small populations Infectious Disease Modeling [pdf] Steve Bellan, Natalie Dean, and Ira Longini contributed to the development of an interactive web-based decision tool, InterVax, to assist in the design of vaccine efcacy trials during emerging outbreaks. This work is part of the ongoing World Health Organization (WHO) Research and Development Blueprint for Action to Prevent Epidemics. CIDID John Drake is a co-author on a paper that will be read at the Royal Statistical Society on March 14, 2018. -
Covid-19 Vaccines Are Coming
COVID-19 VACCINES ARE COMING. ARE WE READY? Etienne Grass – November 2020 On November 9, companies BioNTech and Pfizer 240 COVID vaccines are currently being developed announced the eagerly awaited preliminary results globally, according to the regular census carried out of their phase 3 clinical trial for a COVID vaccine by the World Health Organization. Of these, the project. While it is unusual for this type of result to WHO asserts 45 are in clinical trials2, although only be published before the trial is finalized, the rolling 35 according to the New York Times3. review procedure sanctioned by regulatory bodies to speed up the assessment of new drugs has The WHO says that 10 products are already tested enabled this transparency.1 in phase 3 , a figure that rises to 11 according to the New York Times, which includes the recent progress If the results have come as a positive surprise, it is of an Indian product in its assessment 4. mainly due to their high level of efficacy. The Food and Drug Administration (FDA) had indicated that it Within these phase 3 trials, four products are being would be ready to authorize a vaccine with more tested in China5 and one in Russia6. We do not have than 50% effectiveness. The first figures available the same level of information on them as on are much higher, at 90%. vaccines developed in the United States and Europe. For several weeks now, the head of the "Operation Technological platforms of current projects Warp Speed" program, Moncef Slaoui, who has been piloting American federal activities in support of Five products have in common that they are vaccine production since May, had been telling the integrated into the American (Operation Warp New York Times to be "confident that there will Speed-OWS), British and European partnerships7. -
Herd Immunity Is an Important—And Often Misunderstood—Public Health Phenomenon
CORE CONCEPTS Herd immunity is an important—and often misunderstood—public health phenomenon CORE CONCEPTS Amy McDermott, Science Writer In December, Anthony Fauci predicted that 70 to 85% Since the earliest months of the COVID-19 pan- of the United States population may need to be demic, “herd immunity” has become shorthand for vaccinated to achieve “herd immunity” against SARS- the day when enough people are immune to the virus CoV-2 (1). Yet he was very careful to qualify his com- that social distancing can end and healthcare systems ments. “We need to have some humility here,” he said are no longer overwhelmed. People have been clam- ’ in a New York Times interview, “We really don’t know oring to know when we ll get there. But even as Fauci — what the real number is.” (2) Fauci, director of the and other officials continue to try to calculate and communicate—when it might happen, they have to National Institute of Allergy and Infectious Diseases, contend with both public misunderstanding of the admitted that the number could be as high as 90%. term and scientific disagreement over what it means. But even a year into the pandemic, there were too The public health concept of herd immunity has a many uncertainties to offer a definite threshold. And more nuanced definition than its popular usage, which with vaccine hesitancy widespread, he worried that is one reason why predicting when we’ll achieve it re- setting the bar at such a high number would cause mains difficult. In theory, estimating the threshold to the public to despair of ever reaching it. -
Affidavit from Michael Osterholm
27-CR-20-12951 Filed in District Court State of Minnesota 1/19/2021 3:22 PM STATE OF MINNESOTA DISTRICT COURT COUNTY OF HENNEPIN FOURTH JUDICIAL DISTRICT State of Minnesota, AFFIDAVIT OF MICHAEL T. OSTERHOLM, Ph.D., MPH Plaintiff, V. Derek Michael Chauvin, Court File No.2 27-CR-20-12646 J. Alexander Kueng, Court File No.2 27-CR—20-12953 Thomas Kiernan Lane, Court File No.2 27-CR-20-12951 Tou Thao, Court File No.: 27-CR-20-12949 Defendants. TO: The Honorable Peter Cahill, Judge of District Court, and counsel for Defendants; Eric J. Nelson, Halberg Criminal Defense, 7900 Xerxes Avenue South, Suite 1700, Bloomington, MN 55431; Robert Paule, 920 Second Avenue South, Suite 975, Minneapolis, MN 55402; Earl Gray, 1st Bank Building, 332 Minnesota Street, Suite W1610, St. Paul, MN 55101; Thomas Plunkett, U.S. Bank Center, 101 East Fifth Street, Suite 1500, St. Paul, MN 55101. MICHAEL T. OSTERHOLM, being duly sworn under oath, states as follows: Background and Qualifications 1. My name is Michael Osterholm, and I am an epidemiologist and the director of the Center for Infectious Disease Research and Policy at the University of Minnesota. 2. I am currently a Regents Professor, McKnight Presidential Endowed Chair in Public Health, Distinguished Teaching Professor in the Division of Environmental Health Sciences in the School of Public Health, a professor in the Technological Leadership Institute, and an adjunct professor in the Medical School, all at the University of Minnesota. 27-CR-20-12951 Filed in District Court State of Minnesota 1/19/2021 3:22 PM On November 9, 2020, President-elect Joseph Biden named me to be one of the sixteen members of his Coronavirus Advisory Board. -
The Business Development and International Liaison Team
1st quarter March 2013 March 2013 The Business Development and International Liaison team The Business Development and International Liaison (BDIL) unit would like to take this opportunity to introduce you to the work of the office and to our team. BDIL aims to strengthen and diversify the HSRC's income base by exploring new donor relationships and building research and administrative capacity, while maintaining existing relationships at the strategic and operational level with funders, clients and donors to enable the HSRC to be the research organisation of choice for further work. Vision The vision of the unit is to create an enabling environment for the HSRC to achieve its mandated and strategic objectives by accessing funding opportunities and partnership networks. Partnership Management The BDIL unit provides leadership and support to identify, coordinate and manage strategic international relations and engagements of the HSRC, including the coordination of memoranda of understanding. Who we are Bridgette Prince Michilene Meyer Director [email protected] [email protected] Extension: 8082 Extension: 7968 Billie-Jean Winnaar Carla Pheiffer [email protected] [email protected] Extension: 2519 Extension: 2324 Hema Somai Jothie Moodley [email protected] [email protected] Extension: 7819 Extension: 8006 ASTII Training and Validation Drs Moses Mefika Sithole and Neo Molotja from the Centre for Science and Technology and Innovation Indicators (CeSTII) in the Population Health, Health Systems and Innovation (PHHSI) attended a workshop from 11-15 February 2013, organised by the New Partnership for Africa’s Development (NEPAD) Planning and Coordinating Agency (NPCA) and the African Observatory for Science, Technology and Innovation (AOSTI), in collaboration with the Arab Republic of Egypt. -
Jobs for Young Africans
Formerly ‘Africa Recovery’ United Nations Department of Public Information Vol. 20 No. 3 October 2006 Wanted: jobs for young Africans Reducing Africa’s oil dependence Darfur faces even greater horror Peter Arnold, Inc. / Ron Giling NEPAD in Action African expatriates look homeward Highways link West Africa Promoting ‘responsible tourism’ Solar power: cheap energy for Africa United Nations Vol. 20 No. 3 October 2006 FRI UE ENOUVEAU contentsCover article Wanted: jobs for Africa’s youth ......... .6 Unemployment threatens peace and security . 7 Also in this Issue Darfur facing even greater horror ............ 3 Ghana takes African governance exam ....... 4 Panos / Sven Torfinn What alternatives to oil in Africa?............ 17 NEPAD in action A young auto mechanic in Kenya: Creating jobs for Solar power: women poses particular challenges. cheap energy source for Africa ............ 10 African expatriates look homeward ......... 12 Departments Kenya promotes ‘responsible tourism’ ....... 13 Agenda. .22 Books. 22 Highways link 15 West African countries ................... 14 Briefs. .23 Watch. 24 Cover Photo: Ghanaian worker carries sheets of wood veneer. Africa Renewal is published in English and French by the Strategic Communications Division Editor-in-Chief of the United Nations Department of Public Information, with support from UNDP, UNICEF and Julie I. Thompson UNIFEM. Its contents do not necessarily reflect the views of the United Nations or the pub- lication’s supporting organizations. Material from this magazine may be freely reproduced, -
Vaccine Infodemiology with Jessica Malaty Rivera Ologies Podcast January 5, 2021
Vaccine Infodemiology with Jessica Malaty Rivera Ologies Podcast January 5, 2021 Oh hey, it’s your college roommate who used to mix beer into Metamucil, Alie Ward. The vaccine. Vaccines. Covid-19 vaccines. What is the what? Who gets it? What’s in it? How does it work? When can people make out with strangers again? All good questions which we will get to. But first, some thanks up top to everyone at Patreon.com/Ologies for making this show a reality. You can join for one hot dollar a month. And thank you to everyone who has subscribed, and rated, especially reviewed the show, because you know that I read them like a goblin so I can select a freshie each week. And this one, it’s from LittleGlassFox who said: Thank you, Internet Dad (that’s me) for this beautiful piece of Internet art. I am but a chicken nugget in the sweet and sour ocean of knowledge that is in Ologies. Hop in, folks. Let’s get sticky. Okay, vaccine infodemiology. So, infodemiology: it is a real word and it is the science of managing infodemics, which is also a real word. It’s an overabundance of information, some accurate and some not, occurring during an epidemic. Can you even believe that there is the perfect ology for these times and also the perfect Ologist? So, I was waiting for the right time to do another Coronasode and with the vaccines rolling out, I knew we all had questions. So, about four days ago, I all-caps asked this Ologist that day what her afternoon was like and she’s a champ and hopped on the horn. -
International Collaboration on IP/Access to Medicines: Birth of South Africa’S Fix the Patent Laws Campaign
NYLS Law Review Vols. 22-63 (1976-2019) Volume 60 Issue 2 Twenty Years of South African Constitutionalism: Constitutional Rights, Article 2 Judicial Independence and the Transition to Democracy January 2016 International Collaboration on IP/Access to Medicines: Birth of South Africa’s Fix the Patent Laws Campaign BROOK J. BAKER Professor of Law at Northeastern University School of Law Follow this and additional works at: https://digitalcommons.nyls.edu/nyls_law_review Part of the Intellectual Property Law Commons, and the International Law Commons Recommended Citation BROOK J. BAKER, International Collaboration on IP/Access to Medicines: Birth of South Africa’s Fix the Patent Laws Campaign, 60 N.Y.L. SCH. L. REV. (2015-2016). This Article is brought to you for free and open access by DigitalCommons@NYLS. It has been accepted for inclusion in NYLS Law Review by an authorized editor of DigitalCommons@NYLS. NEW YORK LAW SCHOOL LAW REVIEW VOLUME 60 | 2015/16 VOLUME 60 | 2015/16 Brook K. Baker International Collaboration on IP/Access to Medicines: Birth of South Africa’s Fix the Patent Laws Campaign 60 N.Y.L. Sch. L. Rev. 297 (2015–2016) ABOUT THE AUTHOR: Brook Baker is a Professor of Law at Northeastern University School of Law and an Honorary Research Fellow at the University of KwaZulu-Natal, in Durban, South Africa. www.nylslawreview.com 297 INTERNATIONAL COLLABORATION ON IP/AccESS TO MEDiciNES NEW YORK LAW SCHOOL LAW REVIEW VOLUME 60 | 2015/16 I. INTRODucTION In 2000, my colleague Yousuf Vawda1 and I became active in the global campaign to address intellectual property rights (IPRs), human rights, and barriers to access to affordable medicines for treating HIV and AIDS in South Africa.